Emraclidine Drug Asset Due Diligence Report 2026

This Emraclidine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Emraclidine can convert its Small molecule drug profile and M4 receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Emraclidine (query alias: Emraclidine)
Modality / target	Small molecule drug; M4 receptor; M4 receptor positive allosteric modulator
Highest global status	Phase 2
Originator	Cerevel Therapeutics LLC
Active developers	AbbVie, Inc., Cerevel Therapeutics LLC

The MCP disease footprint includes Schizophrenia, Alzheimer Disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07587008	Phase 1	Completed	12	Primary endpoint not disclosed in English source
NCT07219030	Phase 1	Recruiting	52	Primary endpoint not disclosed in English source
NCT07145918	Phase 2	Recruiting	268	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

Phase 2; n=698; evaluation: Not stated in English source. Reported fields: Any TEAE = 34 Pts ; Any TEAE = 21 Pts

A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis

Phase 2; n=391; evaluation: Not stated in English source. Reported fields: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score(LS Mean) = -16.1 Point (95%CI, -19.4 to -12.8); Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score(LS Mean) = -18.5 Point (95%CI, -22.0 to -15.0)

A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis

Phase 2; n=385; evaluation: Not stated in English source. Reported fields: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score(LS Mean) = -13.5 Unit (95%CI, -17.0 to -10.0); Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score(LS Mean) = -14.7 Unit (95%CI, -18.1 to -11.2)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Emraclidine addresses Schizophrenia, Alzheimer Disease. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2023-12-06	AbbVie Completes Acquisition of Cerevel Therapeutics	Phase 2	US$8,700.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Deuterated 2-(azetidine-3-yl) ethanone compound as well as pharmaceutical composition and application thereof”. The milestone feed surfaced a patent-application signal described as “Heterocyclic carbonyl derivative regulator as well as preparation method and application thereof”. The milestone feed surfaced a patent-application signal described as “Crystal form of emraclidine, preparation method therefor, and use thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO